{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:43:36Z","timestamp":1777045416187,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012022","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000}}],"reference-count":377,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012022.pub2","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T10:31:13Z","timestamp":1596191473000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna AAG","family":"Damen","sequence":"additional","affiliation":[{"name":"Cochrane Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University; Utrecht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[{"name":"Centre for Statistics in Medicine; University of Oxford; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Aldin","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Umlauff","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria DLA","family":"Vazquez-Montes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd; York UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel GM","family":"Moons","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care; University Medical Center Utrecht, Utrecht University; Utrecht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Anton","family":"Kreuzer","sequence":"additional","affiliation":[{"name":"Center of Integrated Oncology Cologne-Bonn, Department I of Internal Medicine; University of Cologne, Faculty of Medicine and University Hospital Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2018.195032","article-title":"Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia","volume":"104","author":"Baliakas","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2018.195032","article-title":"Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia","volume":"104","author":"Baliakas","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Delgado J Doubek M Baumann T Kotaskova J Molica S Mozas P Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI American Journal of Hematology 2017 92 4 375 80","DOI":"10.1002\/ajh.24660"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Delgado J Doubek M Baumann T Kotaskova J Molica S Mozas P Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI American Journal of Hematology 2017 92 4 375 80","DOI":"10.1002\/ajh.24660"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Gentile M Shanafelt TD Mauro FR Laurenti L Rossi D Molica S Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases American Journal of Hematology 2017 93 2 E35 7","DOI":"10.1002\/ajh.24960"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Delgado J Doubek M Baumann T Kotaskova J Molica S Mozas P Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI American Journal of Hematology 2017 92 4 375 80","DOI":"10.1002\/ajh.24660"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Molica S Giannarelli D Mirabelli R Levato L Gentile M Morabito F Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase American Journal of Hematology 2017 92 6 E91 3","DOI":"10.1002\/ajh.24707"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Munoz-Novas C Poza-Santaella M Gonzalez-Gascon YMI Hernandez-Sanchez M Rodriguez-Vicente AE Infante MS The international prognostic index for patients with chronic lymphocytic leukemia has the higher value in predicting overall outcome compared with the Barcelona-Brno biomarkers only prognostic model and the MD Anderson Cancer Center Prognostic Index Biomed Research International 2018 9506979 10.1155\/2018\/9506979","DOI":"10.1155\/2018\/9506979"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2018","journal-title":"Annals of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/ajh.24755","article-title":"Chronic lymphocytic leukemia and prognostic models: a bridge between clinical and biological markers","volume":"92","author":"Reda","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncology"},{"issue":"16","key":"10.1002\/14651858.CD012022.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI Working Group","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncology"},{"issue":"17","key":"10.1002\/14651858.CD012022.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2016-07-724740","article-title":"The CLL-IPI applied in a population-based cohort","volume":"128","author":"Da Cunha-Bang","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Delgado J Doubek M Baumann T Kotaskova J Molica S Mozas P Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI American Journal of Hematology 2017 92 4 375 80","DOI":"10.1002\/ajh.24660"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Gentile M Shanafelt TD Mauro FR Laurenti L Rossi D Molica S Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases American Journal of Hematology 2017 93 2 E35 7","DOI":"10.1002\/ajh.24960"},{"issue":"16","key":"10.1002\/14651858.CD012022.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Molica S Giannarelli D Mirabelli R Levato L Gentile M Morabito F Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase American Journal of Hematology 2017 92 6 E91 3","DOI":"10.1002\/ajh.24707"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Munoz-Novas C Poza-Santaella M Gonzalez-Gascon YMI Hernandez-Sanchez M Rodriguez-Vicente AE Infante MS The international prognostic index for patients with chronic lymphocytic leukemia has the higher value in predicting overall outcome compared with the Barcelona-Brno biomarkers only prognostic model and the MD Anderson Cancer Center Prognostic Index Biomed Research International 2018 9506979 10.1155\/2018\/9506979","DOI":"10.1155\/2018\/9506979"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2018","journal-title":"Annals of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/ajh.24755","article-title":"Chronic lymphocytic leukemia and prognostic models: a bridge between clinical and biological markers","volume":"92","author":"Reda","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"26","key":"10.1002\/14651858.CD012022.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0027|cit27","first-page":"392","article-title":"Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia","volume":"39","author":"Zhu","year":"2018","journal-title":"Chung Hua Hsueh Yeh Hsueh Tsa Chi"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2014-05-575407","article-title":"A new prognostic score for CLL","volume":"124","author":"Tam","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.leukres.2013.02.016","article-title":"The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis","volume":"37","author":"Molica","year":"2013","journal-title":"Leukemia Research"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.24707","article-title":"Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase","volume":"92","author":"Molica","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.12550","article-title":"Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model","volume":"96","author":"Molica","year":"2015","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2018","journal-title":"Annals of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10428190400029965","article-title":"A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia","volume":"46","author":"Molica","year":"2005","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0037|cit37","first-page":"161","article-title":"B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA prognostic indexes","volume":"133","author":"Gonzalez Rodriguez","year":"2009","journal-title":"Medicina Clinica"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.959","article-title":"Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia","volume":"29","author":"Bulian","year":"2011","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.13032","article-title":"Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases","volume":"167","author":"Gentile","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"16","key":"10.1002\/14651858.CD012022.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/leu.2015.333","article-title":"A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients","volume":"30","author":"Gentile","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"10.1002\/14651858.CD012022.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.24004","article-title":"Validation of a new prognostic index for patients with chronic lymphocytic leukemia","volume":"115","author":"Shanafelt","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0045|cit45","first-page":"161","article-title":"B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA prognostic indexes","volume":"133","author":"Gonzalez Rodriguez","year":"2009","journal-title":"Medicina Clinica"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3324\/haematol.2009.011767","article-title":"The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience","volume":"95","author":"Molica","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/leu.2015.333","article-title":"A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients","volume":"30","author":"Gentile","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.leukres.2010.03.014","article-title":"Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: the Gruppo Italiano Studio Linfomi (GISL) experience","volume":"34","author":"Molica","year":"2010","journal-title":"Leukemia Research"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.24707","article-title":"Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase","volume":"92","author":"Molica","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.12550","article-title":"Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model","volume":"96","author":"Molica","year":"2015","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Munoz-Novas C Poza-Santaella M Gonzalez-Gascon YMI Hernandez-Sanchez M Rodriguez-Vicente AE Infante MS The international prognostic index for patients with chronic lymphocytic leukemia has the higher value in predicting overall outcome compared with the Barcelona-Brno biomarkers only prognostic model and the MD Anderson Cancer Center Prognostic Index Biomed Research International 2018 9506979 10.1155\/2018\/9506979","DOI":"10.1155\/2018\/9506979"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2018","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0055|cit55","first-page":"39","article-title":"Multivariable model consisting of clinical and biological markers for time to first treatment in CLL patients: preliminary results from single centre experience","volume":"34","author":"Trajkova","year":"2013","journal-title":"Makedonska Akademija na Naukite i Umetnostite Oddelenie Za Bioloshki i Meditsinski Nauki Prilozi"},{"issue":"31","key":"10.1002\/14651858.CD012022.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/cncr.27900","article-title":"External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia","volume":"119","author":"Molica","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.leukres.2013.02.016","article-title":"The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis","volume":"37","author":"Molica","year":"2013","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12185-014-1634-7","article-title":"A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)\/Rai stage 0 chronic lymphocytic leukemia (CLL)","volume":"100","author":"Molica","year":"2014","journal-title":"International Journal of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.24707","article-title":"Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase","volume":"92","author":"Molica","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2141.2009.07703.x","article-title":"Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia","volume":"146","author":"Morabito","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.23729","article-title":"Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study","volume":"89","author":"Gentile","year":"2014","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/leu.2015.333","article-title":"A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients","volume":"30","author":"Gentile","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.24707","article-title":"Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase","volume":"92","author":"Molica","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/leu.2015.333","article-title":"A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients","volume":"30","author":"Gentile","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-018-3525-0","article-title":"Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort","volume":"98","author":"Rani","year":"2018","journal-title":"Annals of Hematology"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.24125","article-title":"Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients","volume":"90","author":"Stephens","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.24125","article-title":"Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients","volume":"90","author":"Stephens","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.24125","article-title":"Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients","volume":"90","author":"Stephens","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.24125","article-title":"Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.","volume":"90","author":"Stephens","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1080\/10428190600881322","article-title":"Evaluation of clinical staging in chronic lymphocytic leukemia - population-based study","volume":"47","author":"Apelgren","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.V59.6.1191.1191","article-title":"Staging of chronic lymphocytic leukemia","volume":"59","author":"Baccarani","year":"1982","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2014-09-600874","article-title":"Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations","volume":"125","author":"Baliakas","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12288-018-1029-7","article-title":"Prognostic significance of serum BAFF, APRIL, TACI and BCMA levels in chronic lymphocytic leukemia","volume":"35","author":"Berke Mentese","year":"2019","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0082|cit82","first-page":"72","article-title":"Clinical staging of chronic lymphatic leukemia","volume":"77","author":"Bettini","year":"1986","journal-title":"Recenti Progressi in Medicina"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Binet JL Auquier A Dighiero G Chastang C Piguet H Goasguen J A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 1981 48 1 198 206","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-014-2117-x","article-title":"NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment","volume":"93","author":"Bo","year":"2014","journal-title":"Annals of Hematology"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/sj.leu.2403830","article-title":"Mutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?","volume":"19","author":"Bomben","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07469.x","article-title":"Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study","volume":"144","author":"Bomben","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"423174","DOI":"10.1155\/2014\/423174","article-title":"Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients","volume":"2014","author":"Bou Samra","year":"2014","journal-title":"Biomed Research International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012022.pub2-BIB0089|cit89","first-page":"62","article-title":"New prognostic markers of chronic lymphocytic leukemia (CLL) in the everyday hematological practice. An analysis of data from four hematology departments. [Czech]","volume":"16","author":"Brejcha","year":"2010","journal-title":"Transfuze a Hematologie Dnes"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0090|cit90","first-page":"26","article-title":"B-cell chronic lymphocytic leukemia: clinical impact of biological prognostic factors and updated treatment strategies","volume":"129 Suppl 3","author":"Brugiatelli","year":"2007","journal-title":"Lijecnicki Vjesnik"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10654-005-3777-6","article-title":"A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models","volume":"20","author":"Cailliod","year":"2005","journal-title":"European Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2141.1999.01695.x","article-title":"Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome","volume":"107","author":"Callea","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.1989.tb07674.x","article-title":"Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial","volume":"72","author":"Catovsky","year":"1989","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2012.071910","article-title":"Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies","volume":"98","author":"Cesano","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/1042819031000076990","article-title":"Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients","volume":"44","author":"Chang","year":"2003","journal-title":"Leukemia and Lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/sim.4780040307","article-title":"Critical discussion of the assessment of a three-stage prognostic classification for chronic lymphocytic leukemia","volume":"4","author":"Chastang","year":"1985","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2621\u20138","DOI":"10.1002\/cam4.1510","article-title":"Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients","volume":"7","author":"Chauzeix","year":"2018","journal-title":"Cancer Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0100|cit100","first-page":"463","article-title":"Prognostic value of the clinical staging of chronic lymphocytic leukemia (author's transl)","volume":"64","author":"Chelazzi","year":"1979","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000203683","article-title":"Genotypic characterization and multivariate survival analysis of chronic lymphocytic leukemia in Taiwan","volume":"97","author":"Chen","year":"1997","journal-title":"Acta Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0609.2008.01086.x","article-title":"Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies","volume":"81","author":"Chena","year":"2008","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.0007-1048.2001.3205.x","article-title":"CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia","volume":"116","author":"Chevallier","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leukemia & Lymphoma"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood.V84.9.3010.3010","article-title":"Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers","volume":"84","author":"Christiansen","year":"1994","journal-title":"Blood"},{"issue":"13","key":"10.1002\/14651858.CD012022.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","article-title":"Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression","volume":"120","author":"Chuang","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2011.247","article-title":"Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays","volume":"26","author":"Ciccone","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0108|cit108","first-page":"41","article-title":"The staging of chronic lymphatic leukemia. Its prognostic value and therapeutic implications","volume":"40","author":"Ciocoiu","year":"1988","journal-title":"Revista de Medicin\u0103 Intern\u0103, Neurologe, Psihiatrie, Neurochirurgie, Dermato-venerologie"},{"issue":"20","key":"10.1002\/14651858.CD012022.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.2011.39.3090","article-title":"Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia","volume":"30","author":"Claus","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2014-02-555722","article-title":"Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia","volume":"124","author":"Claus","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0111|cit111","first-page":"359","article-title":"Importance of prognostic factors in patients with chronic B-lymphocytic leukemia at the time of diagnosis","volume":"103","author":"Cmunt","year":"2002","journal-title":"Sbornik Lekarsky"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1309\/14XKERAYLUL3H2HT","article-title":"Bimodal cell populations are common in chronic lymphocytic leukemia but do not impact overall survival","volume":"123","author":"Cocco","year":"2005","journal-title":"American Journal of Clinical Pathology"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0113|cit113","first-page":"1078","article-title":"ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia","volume":"90","author":"Corcoran","year":"2005","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","article-title":"p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis","volume":"91","author":"Cordone","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"issue":"16","key":"10.1002\/14651858.CD012022.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional V9V2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD012022.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1997.402686.x","article-title":"Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases","volume":"97","author":"Criel","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hon.888","article-title":"CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL","volume":"27","author":"Cro","year":"2009","journal-title":"Hematological Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0609.2010.01454.x","article-title":"The clinical and biological features of a series of immunophenotypic variant of B-CLL","volume":"85","author":"Cro","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Cuneo","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2018.189837","article-title":"Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study","volume":"103","author":"Cuneo","year":"2018","journal-title":"Haematologica"},{"issue":"1-2","key":"10.1002\/14651858.CD012022.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10428190109097682","article-title":"CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia","volume":"42","author":"D'Arena","year":"2001","journal-title":"Leukemia & Lymphoma"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ajh.20936","article-title":"Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia","volume":"82","author":"D'Arena","year":"2007","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.23170","article-title":"A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia","volume":"87","author":"D'Arena","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3109\/10428194.2014.966245","article-title":"A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia","volume":"56","author":"Dasgupta","year":"2015","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.13940","article-title":"The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with < 97% identity and similar to those with 98% identity","volume":"173","author":"Davis","year":"2016","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jbi.2016.02.017","article-title":"Analysis of clinical prognostic variables for chronic lymphocytic leukemia decision-making problems","volume":"60","author":"DeAndres-Galiana","year":"2016","journal-title":"Journal of Biomedical Informatics"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S1516-31802000000400002","article-title":"Prognosis related to staging systems for chronic lymphocytic leukemia","volume":"118","author":"De Faria","year":"2000","journal-title":"Revista Paulista de Medicina [Sao Paulo Medical Journal]"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2004.04985.x","article-title":"Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery","volume":"126","author":"Degan","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2141.2009.07699.x","article-title":"Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate","volume":"145","author":"Delgado","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.3324\/haematol.2014.108365","article-title":"Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption","volume":"99","author":"Delgado","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2010.028779","article-title":"White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia","volume":"96","author":"Del Giudice","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428190903350421","article-title":"Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia","volume":"51","author":"Del Poeta","year":"2010","journal-title":"Leukemia & Lymphoma"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0136|cit136","first-page":"1468","article-title":"Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia","volume":"89","author":"Del Principe","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood-2005-12-4986","article-title":"Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia","volume":"108","author":"Del Principe","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0138|cit138","first-page":"162","article-title":"Prognosis in chronic lymphocytic leukemia (CLL): experience of the Italian cooperative group (GIMEMA)","volume":"4 Suppl 1","author":"De Rossi","year":"1989","journal-title":"Bone Marrow Transplantation"},{"issue":"30","key":"10.1002\/14651858.CD012022.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1002\/sim.3142","article-title":"Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia","volume":"26","author":"Deslandes","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1011138825593","article-title":"Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine","volume":"12","author":"Di Raimondo","year":"2001","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00277-010-1125-8","article-title":"The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)","volume":"90","author":"Dong","year":"2011","journal-title":"Annals of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s12032-014-0908-5","article-title":"TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia","volume":"31","author":"Dong","year":"2014","journal-title":"Medical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cancergencyto.2008.08.019","article-title":"Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia","volume":"188","author":"Durak","year":"2009","journal-title":"Cancer Genetics and Cytogenetics"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejmhg.2012.03.007","article-title":"Prognostic significance of del 17p, ZAP-70 and CD38 as independent indicators for B-CLL: correlation to response to treatment and disease outcome","volume":"13","author":"El-Kinawy","year":"2012","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.25385","article-title":"IGH translocations in chronic lymphocytic leukemia: clinicopathologic features and clinical outcomes","volume":"94","author":"Fang","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0147|cit147","first-page":"741","article-title":"Prognostic evaluation of chronic lymphocytic leukemia in relation to the Rai classification. Critical analysis of 145 personal cases","volume":"72","author":"Ferrara","year":"1981","journal-title":"Minerva Medica"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1101\/gr.152132.112","article-title":"Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia","volume":"24","author":"Ferreira","year":"2014","journal-title":"Genome Research"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0149|cit149","first-page":"363","article-title":"Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients)","volume":"30","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1988","journal-title":"Nouvelle Revue Fran\u00e7aise d'H\u00e9matologie"},{"issue":"22","key":"10.1002\/14651858.CD012022.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-09-1132","article-title":"A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia","volume":"15","author":"Friedman","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ebiom.2018.05.030","article-title":"Distinct activities of glycolytic enzymes identify chronic lymphocytic leukemia patients with a more aggressive course and resistance to chemo-immunotherapy","volume":"32","author":"Gdynia","year":"2018","journal-title":"EBioMedicine"},{"issue":"11-12","key":"10.1002\/14651858.CD012022.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0145-2126(97)00095-7","article-title":"In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients","volume":"21","author":"Geisler","year":"1997","journal-title":"Leukemia Research"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.12545","article-title":"Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study","volume":"96","author":"Gentile","year":"2016","journal-title":"European Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ejh.13149","article-title":"Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment","volume":"101","author":"Gentile","year":"2018","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1365-2141.2003.04306.x","article-title":"A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression","volume":"121","author":"Giles","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/leu.2017.292","article-title":"Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile","volume":"32","author":"Giudice","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clml.2014.02.007","article-title":"Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia","volume":"14","author":"Gogia","year":"2014","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3324\/haematol.2012.070201","article-title":"CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes","volume":"98","author":"Gonzalez","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0160|cit160","first-page":"84\u201392","article-title":"A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia","volume":"17","author":"Gonzalez-Gascon","year":"2015","journal-title":"Hematological Oncology"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Gonzalez-Rodriguez","year":"2010","journal-title":"Leukemia & Lymphoma"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/blood-2004-11-4394","article-title":"Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status","volume":"105","author":"Grabowski","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/jco.2006.24.18_suppl.6521","article-title":"Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy [abstract]","volume":"24","author":"Grever","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0164|cit164","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.1984.2.6.562","article-title":"Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data","volume":"2","author":"Han","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/leu.2011.125","article-title":"An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia","volume":"25","author":"Herold","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1445-5994.2009.02135.x","article-title":"CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data","volume":"40","author":"Hock","year":"2010","journal-title":"Internal Medicine Journal"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428194.2013.845882","article-title":"Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia","volume":"55","author":"Houldsworth","year":"2014","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/annonc\/mdj120","article-title":"The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia","volume":"17","author":"Hus","year":"2006","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2141.1981.tb07243.x","article-title":"Total tumour mass score (TTM): a new parameter in chronic lymphocyte leukaemia","volume":"49","author":"Jaksic","year":"1981","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0171|cit171","first-page":"219","article-title":"More on early chronic lymphocytic leukemia (CLL): clinical staging systems and indications for treatment","volume":"6","author":"Jaksic","year":"1992","journal-title":"Hematologic Pathology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.12793","article-title":"An old and simple solution for a new problem - more on clinical staging and evaluation of response in B-cell chronic lymphocytic leukaemia in the era of new therapies","volume":"165","author":"Jaksic","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1182\/blood-2006-11-054916","article-title":"CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia","volume":"109","author":"Josefsson","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/1097-0142(19860801)58:3<688::AID-CNCR2820580315>3.0.CO;2-O","article-title":"Immunologic and cytogenetic studies improve prognosis prediction in chronic B-lymphocytic leukemia. A multivariate analysis of 24 variables","volume":"58","author":"Juliusson","year":"1986","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5336\/medsci.2013-37764","article-title":"Prognostic significance of the IgVH mutation status and immunohistochemical analysis of ZAP70 and CD38 in bone marrow biopsies in chronic lymphocytic leukemia","volume":"34","author":"Kahraman Cetin","year":"2014","journal-title":"Turkiye Klinikleri Journal of Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0177|cit177","first-page":"351","article-title":"Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases","volume":"62","author":"Kardum-Skelin","year":"2008","journal-title":"Acta Medica Croatica"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0178|cit178","first-page":"313","article-title":"New parameters of diploid histogram of image DNA cytometry and newly characterized types of nucleolar organizer region structures in defining the proliferative-kinetic index in chronic leukemic lymphoproliferative disorders","volume":"31","author":"Kardum-Skelin","year":"2009","journal-title":"Analytical & Quantitative Cytology & Histology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hon.2900120105","article-title":"The management of chronic lymphocytic leukemia at a single centre over a 24-year period: prognostic factors for survival","volume":"12","author":"Karmiris","year":"1994","journal-title":"Hematological Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/17474086.2018.1442716","article-title":"Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia","volume":"11","author":"Kay","year":"2018","journal-title":"Expert Review of Haematology"},{"issue":"1-2","key":"10.1002\/14651858.CD012022.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009057630","article-title":"Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia","volume":"37","author":"Keating","year":"2000","journal-title":"Leukemia and Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0182|cit182","first-page":"584","article-title":"Epidemiologic, clinical and therapeutic aspects of chronic lymphoid leukemia: apropos of 120 cases","volume":"80","author":"Khalifa","year":"2002","journal-title":"Tunisie Medicale"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1080\/10428190410001714016","article-title":"Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status","volume":"45","author":"Kim","year":"2004","journal-title":"Leukemia and Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hon.2900060108","article-title":"Blood lymphocyte characteristics as predictors of prognosis in chronic lymphocytic leukemia of B-cell type","volume":"6","author":"Kimby","year":"1988","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2017-11-814608","article-title":"Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis","volume":"131","author":"Kleinstern","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.2830020110","article-title":"Chronic lymphocytic leukemia: correlation of clinical course and therapeutic response with in vitro testing and morphology of lymphocytes","volume":"2","author":"Knospe","year":"1977","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0187|cit187","first-page":"195","article-title":"Leukocyte doubling time as a prognostic factor in chronic lymphocytic leukemia","volume":"20","author":"Koberda","year":"1989","journal-title":"Acta Haematologica Polonica"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0188|cit188","first-page":"669","article-title":"Do chromosomal aberrations detected in chronic lymphocytic leukemia patients by conventional cytogenetics with DSP30 have the clinical significance? Preliminary results","volume":"42","author":"Korycka-Wolowiec","year":"2011","journal-title":"Acta Haematologica Polonica"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Krober","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s12032-011-9872-5","article-title":"IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group","volume":"29","author":"Kryachok","year":"2011","journal-title":"Medical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1992.tb08169.x","article-title":"Immunophenotypic subclassification of chronic lymphocytic leukaemia (CLL)","volume":"81","author":"Kurec","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cncr.10772","article-title":"Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia","volume":"95","author":"Lai","year":"2002","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00005-012-0197-7","article-title":"Serum tumor necrosis factor-alpha and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status","volume":"60","author":"Lech-Maranda","year":"2012","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/gcc.22028","article-title":"Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia","volume":"52","author":"Lech-Maranda","year":"2013","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1148\/radiology.204.3.9280265","article-title":"Early chronic lymphocytic leukemia: prognostic value of quantitative bone marrow MR imaging findings and correlation with hematologic variables","volume":"204","author":"Lecouvet","year":"1997","journal-title":"Radiology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2008-01-131359","article-title":"FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia","volume":"112","author":"Li","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"156","DOI":"10.21147\/j.issn.1000-9604.2017.02.09","article-title":"Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China","volume":"29","author":"Li","year":"2017","journal-title":"Chinese Journal of Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bjh.13023","article-title":"Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease","volume":"167","author":"Lin","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"e101063","DOI":"10.1371\/journal.pone.0101063","article-title":"Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia","volume":"9","author":"Lozano-Santos","year":"2014","journal-title":"PLOS One"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.3109\/10428194.2015.1023800","article-title":"Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997","volume":"56","author":"Lucas","year":"2015","journal-title":"Leukemia and Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.leu.2404650","article-title":"Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status","volume":"21","author":"Maffei","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood-2009-11-252494","article-title":"Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia","volume":"116","author":"Maffei","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.1987.5.3.398","article-title":"Prognosis in chronic lymphocytic leukemia: a retrospective multicentric study from the GIMEMA group","volume":"5","author":"Mandelli","year":"1987","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23466","article-title":"Short telomere length is associated with NOTCH1\/SF3B1\/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients","volume":"88","author":"Mansouri","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1525-1578(10)60589-2","article-title":"Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia","volume":"7","author":"Marasca","year":"2005","journal-title":"Journal of Molecular Diagnostics"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/hon.2028","article-title":"Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone","volume":"31","author":"Marasca","year":"2013","journal-title":"Hematological Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.leukres.2007.09.002","article-title":"Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis","volume":"32","author":"Martinelli","year":"2008","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<143::AID-AJH7>3.0.CO;2-Y","article-title":"Decision-tree approach to the immunophenotype-based prognosis of the B-cell chronic lymphocytic leukemia","volume":"59","author":"Masic","year":"1998","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0211|cit211","first-page":"429","article-title":"A predictive model for survival of patients with chronic lymphocytic leukemia - results of a multivariate survival analysis","volume":"6","author":"Mateva","year":"2001","journal-title":"Journal of the Balkan Union of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1600-0609.2006.00707.x","article-title":"Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression","volume":"77","author":"Matthews","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.leukres.2006.03.028","article-title":"V(H)3-48 and V(H)3-53, as well as V(H)3-21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous LCDR3 sequences and poor prognosis","volume":"31","author":"Matthews","year":"2007","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/leu.2012.209","article-title":"The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry","volume":"27","author":"Matutes","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1080\/10428194.2017.1295149","article-title":"Predicting time to first treatment in early stage CLL: scores, values and comparative prognostic models","volume":"58","author":"Matutes","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1987.tb06130.x","article-title":"The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features","volume":"65","author":"Melo","year":"1987","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1663\u20139","DOI":"10.1007\/s00277-018-3359-9","article-title":"A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion","volume":"97","author":"Miao","year":"2018","journal-title":"Annals of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/030089168407000502","article-title":"Prognosis of chronic lymphocytic leukemia: analysis of one hundred cases","volume":"70","author":"Molica","year":"1984","journal-title":"Tumori"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/030089168607200604","article-title":"Prognostic value of \"total tumor mass score\" (TTM): a retrospective analysis of 130 patients with chronic lymphocytic leukemia","volume":"72","author":"Molica","year":"1986","journal-title":"Tumori"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-0609.1988.tb00870.x","article-title":"Investigation of nuclear clefts as a prognostic parameter in chronic lymphocytic leukemia","volume":"41","author":"Molica","year":"1988","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V78.4.895.895","article-title":"Progression and survival studies in early chronic lymphocytic leukemia","volume":"78","author":"Molica","year":"1991","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1994.tb00648.x","article-title":"Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases","volume":"52","author":"Molica","year":"1994","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.1998.tb00995.x","article-title":"Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins","volume":"60","author":"Molica","year":"1998","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.1999.tb01731.x","article-title":"Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia","volume":"62","author":"Molica","year":"1999","journal-title":"European Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0225|cit225","first-page":"1094","article-title":"Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival","volume":"84","author":"Molica","year":"1999","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/10428190701760045","article-title":"Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia","volume":"49","author":"Molica","year":"2008","journal-title":"Leukemia and Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood.V78.6.1545.1545","article-title":"Presenting features and prognosis of chronic lymphocytic leukemia in younger adults","volume":"78","author":"Montserrat","year":"1991","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0145-2126(01)00049-2","article-title":"Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia","volume":"25","author":"Morabito","year":"2001","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bjh.13117","article-title":"Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study","volume":"168","author":"Morabito","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.leukres.2015.05.005","article-title":"Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment","volume":"39","author":"Morabito","year":"2015","journal-title":"Leukemia Research"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.25206","article-title":"Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: mutational load or mutational status? Analysis of 1003 cases","volume":"93","author":"Morabito","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/bjh.15397","article-title":"Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study","volume":"185","author":"Moreno","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1080\/10428190802360810","article-title":"Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL","volume":"49","author":"Morilla","year":"2008","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-017-3176-x","article-title":"Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States","volume":"17","author":"Nabhan","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0235|cit235","first-page":"520","article-title":"The prognostic significance of interphase cytogenetic abnormalities in chronic lymphocytic leukemia","volume":"35","author":"Nedeva","year":"2018","journal-title":"Archives of Hellenic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0236|cit236","first-page":"49","article-title":"A study of prognostic factors in patients with chronic lymphocytic leukemia","volume":"5","author":"Nenova","year":"2000","journal-title":"Journal of Bulkan Union of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/10428194.2013.786070","article-title":"CD38 variation as a prognostic factor in chronic lymphocytic leukemia","volume":"55","author":"Nipp","year":"2014","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.20137","article-title":"Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma","volume":"77","author":"Nola","year":"2004","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2008.17.0795","article-title":"Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia","volume":"27","author":"Nowakowski","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/10428190500464161","article-title":"Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia","volume":"47","author":"Nuckel","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1600-0609.2009.01328.x","article-title":"FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia","volume":"83","author":"Nuckel","year":"2009","journal-title":"European Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment","volume":"82","author":"O'Brien","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3324\/haematol.10649","article-title":"The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells","volume":"92","author":"Ocana","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/10428194.2010.545463","article-title":"Prospective study of clinical and biological prognostic factors at diagnosis in patients with early stage B-cell chronic lymphocytic leukemia","volume":"52","author":"Oliveira","year":"2011","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fonc.2019.00079","article-title":"Time to treatment prediction in chronic lymphocytic leukemia based on new transcriptional patterns","volume":"9","author":"Orgueira","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.1990.tb06367.x","article-title":"Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia","volume":"76","author":"Oscier","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1097-0142(19840715)54:2<339::AID-CNCR2820540227>3.0.CO;2-H","article-title":"Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases","volume":"54","author":"Paolino","year":"1984","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10428194.2016.1180690","article-title":"COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status","volume":"58","author":"Plesingerova","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0249|cit249","first-page":"490","article-title":"Multivariate analysis of prognostic factors in chronic lymphocytic leukemia","volume":"21","author":"Prokocimer","year":"1985","journal-title":"Israel Journal of Medical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41408-017-0014-y","article-title":"MYD88 mutations predict unfavorable prognosis in chronic lymphocytic leukemia patients with mutated IGHV gene","volume":"7","author":"Qin","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact","volume":"29","author":"Queiros","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0889-8588(18)30497-0","article-title":"Prognostic factors and clinical staging in chronic lymphocytic leukemia","volume":"4","author":"Rai","year":"1990","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdy021","article-title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","volume":"29","author":"Raponi","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD012022.pub2-BIB0255|cit255","first-page":"368","article-title":"Significance and independence of the immunologic, histological, and clinical features as prognostic factors in chronic lymphatic leukemia","volume":"74","author":"Resegotti","year":"1989","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.28884","article-title":"Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia","volume":"135","author":"Rissiek","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/sj.leu.2404831","article-title":"Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation","volume":"21","author":"Rodriguez","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1038\/bcj.2016.77","article-title":"lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome","volume":"6","author":"Ronchetti","year":"2016","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/039139888600900112","article-title":"Depletion lymphocytapheresis in chronic lymphocytic leukemias: criteria for predicting which patients will respond to treatment","volume":"9","author":"Rossi","year":"1986","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1479-5876-8-23","article-title":"Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T\/B ratio versus percentage of positive cells","volume":"8","author":"Rossi","year":"2010","journal-title":"Journal of Translational Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2010-01-263889","article-title":"MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival","volume":"116","author":"Rossi","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0263|cit263","first-page":"265","article-title":"Chronic lymphoid leukemia. Survival in relation to clinical stages. Statistical analysis of 95 cases","volume":"72","author":"Rozman","year":"1979","journal-title":"Medicina Clinica"},{"issue":"5-6","key":"10.1002\/14651858.CD012022.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10428199509054432","article-title":"A scoring system for the classification of CD5-B CLL versus CD5+ B CLL and B PLL","volume":"16","author":"Salomon-Nguyen","year":"1995","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/030089167906500105","article-title":"Clinical classification and survival in chronic lymphocyte leukemia","volume":"65","author":"Santoro","year":"1979","journal-title":"Tumori"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0266|cit266","first-page":"305","article-title":"Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype, soluble CD23 and morphology","volume":"62","author":"Sarmiento","year":"2002","journal-title":"Medicina"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1109\/TBME.2016.2533658","article-title":"A personalized framework for dynamic modeling of disease trajectories in chronic lymphocytic leukemia","volume":"63","author":"Savvopoulos","year":"2016","journal-title":"IEEE Transactions on Biomedical Engineering"},{"issue":"4-5","key":"10.1002\/14651858.CD012022.pub2-BIB0268|cit268","first-page":"205","article-title":"Prognosis of chronic lymphatic leukemia. Retrospective study of the survival period 47 patients","volume":"72","author":"Scolozzi","year":"1981","journal-title":"Minerva Medica"},{"issue":"20","key":"10.1002\/14651858.CD012022.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","volume":"116","author":"Shanafelt","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0271|cit271","first-page":"91","article-title":"Risk factors in chronic lymphocytic leukemia, validation of flow cytometric detection using RT-PCR and immunohistochemistry","volume":"15","author":"Spacek","year":"2009","journal-title":"Transfuze a Hematologie Dnes"},{"issue":"21","key":"10.1002\/14651858.CD012022.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/blood-2008-11-189407","article-title":"MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification","volume":"113","author":"Stamatopoulos","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2016.307","article-title":"Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0274|cit274","first-page":"217","article-title":"Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial","volume":"10","author":"Strefford","year":"2015","journal-title":"Leukemia"},{"issue":"27","key":"10.1002\/14651858.CD012022.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"19136","DOI":"10.18632\/oncotarget.24927","article-title":"Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease","volume":"9","author":"Szymczyk","year":"2018","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jgo.2018.03.018","article-title":"Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)","volume":"9","author":"Tallarico","year":"2018","journal-title":"Journal of Geriatric Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/2000-1967-075","article-title":"The immunoglobulin genes and chronic lymphocytic leukemia (CLL)","volume":"110","author":"Tobin","year":"2005","journal-title":"Upsala Journal of Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0278|cit278","first-page":"465","article-title":"Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome","volume":"90","author":"Tobin","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1073\/pnas.1211130110","article-title":"Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia","volume":"110","author":"Vallat","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/epi.22674","article-title":"HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance","volume":"7","author":"Van Damme","year":"2012","journal-title":"Epigenetics"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0281|cit281","first-page":"82","article-title":"Clinical staging of chronic lymphocytic leukaemia and its relationship to survival","volume":"65","author":"Velardi","year":"1980","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1080\/10428194.2017.1285027","article-title":"Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia","volume":"58","author":"Vojdeman","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0283|cit283","first-page":"179","article-title":"Comparison of CD38, ZAP70 and hTERT expression with known prognostic markers in patients with chronic lymphocytic leukemia during five-year follow- up period","volume":"24","author":"Vural","year":"2014","journal-title":"Uluslararasi Hematoloji-Onkoloji Dergisi (UHOD)"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ajh.20987","article-title":"Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia","volume":"82","author":"Weinberg","year":"2007","journal-title":"American Journal of Hematology"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.25752","article-title":"Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia","volume":"117","author":"Weiss","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2141.2003.04118.x","article-title":"Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia","volume":"120","author":"Wierda","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3324\/haematol.2010.025734","article-title":"Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk","volume":"95","author":"Winkler","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0288|cit288","first-page":"136","article-title":"Applicability of different clinical staging systems in chronic lymphocytic leukemia for Chinese patients","volume":"19","author":"Wu","year":"2010","journal-title":"Journal of Leukemia and Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/10245332.1997.11746327","article-title":"Comparison of Rai and Binet classifications in chronic lymphocytic leukemia","volume":"2","author":"Zengin","year":"1997","journal-title":"Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3109\/10428190903207530","article-title":"BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia","volume":"50","author":"Zenz","year":"2009","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jcp.20570","article-title":"A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia","volume":"207","author":"Zucchetto","year":"2006","journal-title":"Journal of Cellular Physiology"},{"issue":"7","key":"10.1002\/14651858.CD012022.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3109\/10428194.2011.578311","article-title":"Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling","volume":"52","author":"Antic","year":"2011","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.959","article-title":"Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia","volume":"29","author":"Bulian","year":"2011","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1479-5876-10-18","article-title":"IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia","volume":"10","author":"Bulian","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.3324\/haematol.2016.154450","article-title":"Integration of B-cell receptor-induced ERK1\/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-na\u00efve chronic lymphocytic leukemia","volume":"102","author":"Cavallini","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/cncr.21437","article-title":"Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia","volume":"104","author":"Del Giudice","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.leukres.2010.10.002","article-title":"High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia","volume":"35","author":"Friedrichs","year":"2011","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0299|cit299","first-page":"64","article-title":"Chronic lymphocytic leukemia: a retrospective analysis of diagnostic characteristics and survival predictive factors in 150 patients","volume":"16","author":"Furundarena Salsamendi","year":"1994","journal-title":"Biologia y Clinica Hematologica"},{"issue":"6","key":"10.1002\/14651858.CD012022.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3324\/haematol.2009.005561","article-title":"Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages","volume":"94","author":"Gentile","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/gcc.20794","article-title":"Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters","volume":"49","author":"Haferlach","year":"2010","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0302|cit302","first-page":"285","article-title":"Chronic lymphatic leukemia. II. Analysis of prognostic factors and development of survival predicting models. Study of 187 patients","volume":"36","author":"Jarque","year":"1991","journal-title":"Sangre"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.V69.3.929.929","article-title":"Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients","volume":"69","author":"Lee","year":"1987","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.thj.6200055","article-title":"Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia","volume":"1","author":"Leotard","year":"2000","journal-title":"Hematology Journal"},{"issue":"22","key":"10.1002\/14651858.CD012022.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood-2010-06-288274","article-title":"Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters","volume":"116","author":"Letestu","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0306|cit306","first-page":"135","article-title":"Chronic lymphocytic leukemia prognostic index: a new integrated scoring system to predict the Time to First Treatment in Chinese patients with chronic lymphocytic leukemia","volume":"130","author":"Li","year":"2017","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1309\u201315","DOI":"10.1007\/s00432-018-2663-z","article-title":"The prognostic role of HBV infection in chronic lymphocytic leukemia","volume":"144","author":"Liang","year":"2018","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1097-0215(20000920)89:5<440::AID-IJC7>3.0.CO;2-U","article-title":"Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia","volume":"89","author":"Metze","year":"2000","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/atm.2019.03.63","article-title":"SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients","volume":"7","author":"Miao","year":"2019","journal-title":"Annals of Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0609.1990.tb00395.x","article-title":"Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance","volume":"44","author":"Molica","year":"1990","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.2010.01482.x","article-title":"Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia","volume":"85","author":"Molica","year":"2010","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2014.09.003","article-title":"Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis","volume":"15","author":"Molica","year":"2015","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","article-title":"A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients","volume":"60","author":"Molica","year":"2019","journal-title":"Leukemia & Lymphoma"},{"issue":"24","key":"10.1002\/14651858.CD012022.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/blood-2011-04-345587","article-title":"The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2141.2011.08974.x","article-title":"Defining the prognosis of early stage chronic lymphocytic leukaemia patients","volume":"156","author":"Pepper","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hon.2520","article-title":"Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables","volume":"36","author":"Qin","year":"2018","journal-title":"Hematological Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V59.5.1001.1001","article-title":"Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases","volume":"59","author":"Rozman","year":"1982","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","article-title":"Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases","volume":"64","author":"Rozman","year":"1984","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"e28277","DOI":"10.1371\/journal.pone.0028277","article-title":"A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia","volume":"6","author":"Schweighofer","year":"2011","journal-title":"PLOS One"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"e12780","DOI":"10.1371\/journal.pone.0012780","article-title":"A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients","volume":"5","author":"Stamatopoulos","year":"2010","journal-title":"PLOS One"},{"issue":"29","key":"10.1002\/14651858.CD012022.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","article-title":"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center","volume":"25","author":"Tsimberidou","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjh.15498","article-title":"Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses","volume":"183","author":"Vetro","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clml.2015.06.001","article-title":"Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia","volume":"15","author":"Visentin","year":"2015","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0324|cit324","doi-asserted-by":"crossref","unstructured":"Wierda WG O'Brien S Wang X Faderl S Ferrajoli A Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment Journal of Clinical Oncology 2009 27 10 1637 43","DOI":"10.1200\/JCO.2008.18.1701"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0325|cit325","unstructured":"Rituximab, fludarabine, and cyclophosphamide or observation alone in treating patients with stage 0, stage I, or stage II chronic lymphocytic leukemia clinicaltrials.gov\/ct2\/show\/NCT00275054"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0326|cit326","unstructured":"A prognostic tool for early stage CLL clinicaltrials.gov\/ct2\/show\/NCT03436524"},{"issue":"14","key":"10.1002\/14651858.CD012022.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: users guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD012022.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001221","article-title":"Reporting and methods in clinical prediction research: a systematic review","volume":"9","author":"Bouwmeester","year":"2012","journal-title":"PLOS Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD012022.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/L15-5093-2","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)","volume":"162","author":"Collins","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40140-016-0171-8","article-title":"Risk prediction models in perioperative medicine: methodological considerations","volume":"6","author":"Collins","year":"2016","journal-title":"Current Anesthesiology Reports"},{"issue":"23","key":"10.1002\/14651858.CD012022.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/sim.5412","article-title":"Aggregating published prediction models with individual participant data: a comparison of different approaches","volume":"31","author":"Debray","year":"2012","journal-title":"Statistics in Medicine"},{"issue":"14","key":"10.1002\/14651858.CD012022.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/sim.6080","article-title":"Meta-analysis and aggregation of multiple published prediction models","volume":"33","author":"Debray","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"i6460","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1177\/0962280218785504","article-title":"A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes","volume":"28","author":"Debray","year":"2018","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0337|cit337","unstructured":"metamisc: Diagnostic and prognostic meta-Analysis. R package version 0.1.9 Debray T de Jong V R Foundation for Statistical Computing 2018"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2009","journal-title":"Leukemia"},{"issue":"26","key":"10.1002\/14651858.CD012022.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012022.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"El Rouby","year":"1993","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD012022.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood.V128.22.2019.2019","article-title":"Prognostic impact of the new CLL-IPI Index in a single center CLL Spanish cohort","volume":"128","author":"Ferrer Lores","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"e32844","DOI":"10.1371\/journal.pone.0032844","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/11587650-000000000-00000","article-title":"Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly","volume":"28","author":"Goede","year":"2012","journal-title":"Drugs and Aging"},{"issue":"22","key":"10.1002\/14651858.CD012022.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood.V128.22.4401.4401","article-title":"Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in elderly patients with comorbidities: analysis of the CLL11 study population","volume":"128","author":"Goede","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD012022.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12916-018-1099-2","article-title":"Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement","volume":"16","author":"Heus","year":"2018","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0350|cit350","unstructured":"Howlader N Noone AM Krapcho M Miller D Brest A Yu M National Cancer Institute SEER Cancer Statistics Review, 1975-2016 www.seer.cancer.gov\/archive\/csr\/1975_2016 (based on November 2018 SEER data submission, posted to the SEER web site, April 2019)"},{"issue":"9","key":"10.1002\/14651858.CD012022.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.leu.2404802","article-title":"The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia","volume":"21","author":"Kay","year":"2007","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0352|cit352","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions V ersion 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD012022.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-018-3350-5","article-title":"Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis","volume":"97","author":"Molica","year":"2018","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2017-09-806034","article-title":"Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis","volume":"131","author":"Molica","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"b375","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/sim.2324","article-title":"Confidence intervals for an effect size measure based on the Mann\u2013Whitney statistic. Part 2: asymptotic methods and evaluation","volume":"25","author":"Newcombe","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"l2154","DOI":"10.1136\/bmj.l2154","article-title":"When and how to use data from randomised trials to develop or validate prognostic models","volume":"365","author":"Pajouheshnia","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"e1001671","DOI":"10.1371\/journal.pmed.1001671","article-title":"Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols","volume":"11","author":"Peat","year":"2014","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"e1001380","DOI":"10.1371\/journal.pmed.1001380","article-title":"Prognosis research strategy (PROGRESS) 2: Prognostic factor research","volume":"10","author":"Riley","year":"2013","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD012022.pub2-BIB0365|cit365","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780198796619.001.0001","volume-title":"Prognosis Research in Healthcare. Concepts, Methods, and Impact","author":"Riley","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2003-07-2281","article-title":"Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL","volume":"103","author":"Shanafelt","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012022.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"e1001381","DOI":"10.1371\/journal.pmed.1001381","article-title":"Prognosis Research Strategy (PROGRESS) 3: prognostic model research","volume":"10","author":"Steyerberg","year":"2013","journal-title":"PLOS Medicine"},{"issue":"29","key":"10.1002\/14651858.CD012022.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD012022.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"4","key":"10.1002\/14651858.CD012022.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0609.2008.01114.x","article-title":"Disease burden of chronic lymphocytic leukaemia within the European Union","volume":"81","author":"Watson","year":"2008","journal-title":"European Journal of Haematology"},{"issue":"31","key":"10.1002\/14651858.CD012022.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012022.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ajh.23546","article-title":"Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice","volume":"88","author":"Zaja","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD012022.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2011.02.002","article-title":"Importance of genetics in chronic lymphocytic leukemia","volume":"25","author":"Zenz","year":"2011","journal-title":"Blood Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012022.pub2-BIB0377|cit377","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012022","article-title":"Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis","author":"Skoetz","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T20:01:34Z","timestamp":1723579294000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012022.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":377,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012022.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}